

Supplementary Table 1: Participant characteristics in the discovery and replication cohorts

	Discovery cohort		Replication cohort
	General population (n=951)	Obesity clinic (n=1179)	GALA-ALD/HP (n=558)
Age, mean (s.d.), y	12 (3)	12 (3)	56 (10)
Female sex, No. (%)	530 (56)	641 (54)	148 (73)
Male sex, No. (%)	421 (44)	538 (46)	410 (27)
BMI, mean (s.d.), kg/m <sup>2</sup>	17.7 (2.3)	27.1 (5.6)	27.2 (5)
BMI SDS, mean (s.d.)	-0.05 (0.81)	2.77 (0.75)	NA
Tanner stage 1/2-5, No. (%)	233/474 (33/67)	327/569 (36/64)	NA
ALT, median (IQR), U/L	19 (16-23)	24 (19-31)	28 (21-42)
AST, median (IQR), U/L	26 (22-31)	24 (20-29)	30 (24-46)
GGT, median (IQR), U/L	16 (12-19)	17 (15-21)	48 (25-136)
Glucose, median (IQR), mmol/L	5 (4.7-5.2)	5 (4.8-5.3)	6 (5.5-6.6)
Insulin, median (IQR), pmol/L	51 (36.3-68.4)	79 (55.1-117.8)	NA
HbA1c, median (IQR), mmol/mol	34 (32-35)	34 (32-36)	36 (33-39)
Triglycerides, median (IQR), mmol/L	0.6 (0.5-0.8)	0.9 (0.7-1.3)	1.2 (0.9-1.8)
Total cholesterol, median (IQR), mmol/L	3.9 (3.5-4.3)	4 (3.6-4.6)	5 (4.4-5.9)
LDL cholesterol, median (IQR), mmol/L	2 (1.7-2.4)	2.3 (1.9-2.8)	3 (2.3-3.6)
HDL cholesterol, median (iQR), mmol/L	1.5 (1.3-1.8)	1.2 (1-1.4)	1.3 (1.1-1.7)
Abstaining from alcohol at time of inclusion, No. (%)	NA	NA	197 (35)
Statin use prior time of inclusion, No. (%)	NA	NA	97 (17)
Steatosis 0/1/2/3, No.	NA	NA	373/79/70/36
Inflammatory activity 0/1/2/3/4/5, No.	NA	NA	290/90/78/50/28/22
Fibrosis stage 0-1/2/3/4, No.	NA	NA	367/102/26/63

BMI=body mass index; SDS=standard deviation score; IQR= Interquartile range; ALT=alanine aminotransferase; AST=aspartate aminotransferase; GGT=gamma glutamyl transferase; HbA1C=hemoglobin A1c; LDL=low-density lipoprotein; HDL=high-density lipoprotein.